南下資金持續加倉,藥明生物續漲9%,市值重返兩千億
格隆匯11月7日丨上交易日大漲逾10%的藥明生物(2269.HK)今日再度走強,現報47.4港元,漲幅9.34%,總市值2000.1億港元。

資料顯示,該股在11月4日再度獲南下資金淨買入7.8922億港元,10月25日至11月4日連續9個交易日累計獲淨買入55.1億港元。
此外,有消息稱,全球知名藥企阿斯利康5日在第五屆中國國際進口博覽會期間舉行江蘇成果發佈活動。阿斯利康宣佈將在無錫全球供應基地投資1億元,用於引進治療高鉀血癥專用藥物利倍卓新產線,並將阿斯利康全球耐信針劑生產整合到無錫供應基地,加速推動創新藥的本地化生產供應。阿斯利康宣佈與無錫藥明生物共同推進新冠預防中和抗體組合藥物Evusheld的原液出口供應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.